Skip to main
PMN

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences Inc. exhibits a promising trajectory in its clinical-stage development of antibody therapeutics, bolstered by favorable biomarker and safety data that support the continued investment in its lead candidate, PMN310. The company’s innovative approach highlights PMN267's dual selectivity profile, which is anticipated to enhance its potential in treating multiple neurodegenerative diseases, thus broadening its development horizon. Additionally, the absence of adverse reactions such as ARIA in PMN310 positions it favorably against competitive products, suggesting a superior safety profile that may attract further investor confidence and drive future growth.

Bears say

ProMIS Neurosciences Inc. reported a substantial net loss of $11.6 million for Q3 2025, equating to a loss of $0.24 per share, underscoring ongoing financial challenges as the company remains unprofitable. Significant risks linger in potential future partnerships and a slower-than-anticipated market uptake, primarily due to heightened competition in the biotechnology sector. Moreover, the company's reliance on a novel therapeutic approach targeting toxic Aβ oligomers faces hurdles, especially following the lack of efficacy observed in clinical trials for similar therapies, raising concerns about the effectiveness and commercial viability of their products.

PMN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 3 analysts, PMN has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.